Aligos Therapeutics extends South San Francisco headquarters lease to 2034
The company amended its lease with landlord Britannia Biotech Gateway, pushing the expiration from 2027 to 2034 with new rent terms and early termination options.
SEC filing
Latest
4 stories
Tuesday, September 15
Thursday, August 6
Aligos reports Q2 2026 results, pevifoscorvir sodium enrollment complete
Aligos said its Phase 2 B-SUPREME study of pevifoscorvir sodium has finished enrolling patients, with topline data expected in late Q3 2027, as partner Amoytop advances an HBV antisense program in China.
SEC filing